Abstract
Small interfering RNA (siRNA) has become a specific and powerful tool to turn off the expression of target genes, and has turned into a promising tool in molecular medicine. It can be targeted against cancer by several strategies. These include the suppression of overexpressed oncogenes, retarding cell division by interfering with cyclins and related genes or enhancing apoptosis by inhibiting anti-apoptotic genes. RNA interference (RNAi) against multidrug resistance (MDR) genes or chemo/radio-resistance and angiogenesis targets may also provide beneficial cancer treatments. Successful cancer therapy by siRNA in vitro and in vivo provides the enthusiasm for potential therapeutic applications of this technique. Here, we review RNAi in cancer therapy, highlighting recent progress and examining the hurdles that must be overcome before this promising technology is ready for clinical use.
Keywords: Small interfering RNA, pharmacodynamics, cancer, oncogene, apoptosis, cell cycle, angiogenesis, multidrug resistance, oncogenes, cyclins, anti-apoptotic genes, Carcinogenesis Pathways, Viral Oncogenes, Radiotherapy/Chemotherapy Resistance
Mini-Reviews in Medicinal Chemistry
Title: Small Interfering RNA for Effective Cancer Therapies
Volume: 11 Issue: 2
Author(s): X. Wang, Y. Chen, J. Ren and X. Qu
Affiliation:
Keywords: Small interfering RNA, pharmacodynamics, cancer, oncogene, apoptosis, cell cycle, angiogenesis, multidrug resistance, oncogenes, cyclins, anti-apoptotic genes, Carcinogenesis Pathways, Viral Oncogenes, Radiotherapy/Chemotherapy Resistance
Abstract: Small interfering RNA (siRNA) has become a specific and powerful tool to turn off the expression of target genes, and has turned into a promising tool in molecular medicine. It can be targeted against cancer by several strategies. These include the suppression of overexpressed oncogenes, retarding cell division by interfering with cyclins and related genes or enhancing apoptosis by inhibiting anti-apoptotic genes. RNA interference (RNAi) against multidrug resistance (MDR) genes or chemo/radio-resistance and angiogenesis targets may also provide beneficial cancer treatments. Successful cancer therapy by siRNA in vitro and in vivo provides the enthusiasm for potential therapeutic applications of this technique. Here, we review RNAi in cancer therapy, highlighting recent progress and examining the hurdles that must be overcome before this promising technology is ready for clinical use.
Export Options
About this article
Cite this article as:
Wang X., Chen Y., Ren J. and Qu X., Small Interfering RNA for Effective Cancer Therapies, Mini-Reviews in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/138955711794519528
DOI https://dx.doi.org/10.2174/138955711794519528 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews Evaluation of the Oxidative Stress Level and Serum Prolidase Activity in Patients with Sleep Bruxism
Combinatorial Chemistry & High Throughput Screening Predicting Cancer-Related MiRNAs Using Expression Profiles in Tumor Tissue
Current Pharmaceutical Biotechnology Fiber-Optic Technologies in Laser-Based Therapeutics: Threads for a Cure
Current Pharmaceutical Biotechnology Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Saccharomyces Cerevisiae as a Genetic Model in Anticancer Therapy
Current Pharmacogenomics Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Antitumor Activity of Cyclodextrin-based Supramolecular Platinum Prodrug In vitro and In vivo
Letters in Drug Design & Discovery Anti-inflammatory Action of Green Tea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Cancer Chemoprevention with Green Tea Catechins: From Bench to Bed
Current Drug Targets The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology Protein Interaction Networks in Metallo Proteins and Docking Approaches of Metallic Compounds with TIMP and MMP in Control of MAPK Pathway
Letters in Drug Design & Discovery 4,7-Dihydroindole: A Synthon for the Preparations of 2-Substituted Indoles
Current Organic Synthesis